Protein S Deficiency, Activated Protein C Resistance and Sticky Platelet Syndrome in a Young Woman with Bilateral StrokesChaturvedi S.a · Dzieczkowski J.S.b
aDepartment of Neurology, Wayne State University School of Medicine / Detroit Medical Center and bDepartment of Medicine, Indiana University School of Medicine, Detroit, Mich., USA
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Background: Coagulation disorders are common in young adults (age less than 55 years) with ischemic stroke. Objectives: To describe a young woman with bilateral strokes of undetermined etiology who had three significant hemostatic disturbances. These were protein S deficiency, Factor V Leiden heterozygosity, and sticky platelet syndrome. The Factor V Leiden mutation was also present in one of her children. Conclusions: Young patients with cryptogenic stroke warrant a thorough evaluation for hypercoagulable states. More than one coagulation disorder can coexist in the same patient and the spectrum of hemostatic abnormalities may influence the patient’s treatment and may have implications for screening of other family members.
- Nachman RL, Silverstein RL: Hypercoagulable states. Ann Intern Med 1993;119:819–827.
- Heijboer H, Brandjes DP, Buller HR, Sturk A, ten Cate JW: Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med 1990;323:1512–1516.
Coull BW, Clark WM: Abnormalities of hemostasis in ischemic stroke. Med Clin North Am 1993;77(1):77–94.
- Martinez HR, Rangel-Guerra RA, Marfil LJ: Ischemic stroke due to deficiency of coagulation inhibitors. Report of 10 young adults. Stroke 1993;24:19–25.
- Dahlback B, Hildebrand B: Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci USA 1994;91:1396–1400.
- Bertina RM, Koeleman B, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64–67.
Mammen EF: Ten years’ experience with the sticky platelet syndrome. Clin Appl Thromb Hemost 1995;1:66–72.
Jorquera JI, Montoro JM, Fernandez MA, Aznar JA, Aznar J: Modified test for activated protein C resistance. Lancet 1994;344:1162–1163.
- Comp PC, Nixon PR, Cooper MR, Esmon CT: Familial protein S deficiency is associated with recurrent thrombosis. J Clin Invest 1984;74:2082.
- Engesser L, Broekmans AW, Briet E, Brommer EJ, Bertina RM: Hereditary protein S deficiency: Clinical manifestations. Ann Intern Med 1987;106:677–682.
- Allaart CF, Aronson DC, Ruys T, Rosendaal FR, van Bockel JH, Bertina RM, Briet E: Hereditary protein S deficiency in young adults with arterial occlusive disease. Thromb Haemost 1990;64:206–210.
Girolami A, Simioni P, Lazzaro AR, Cordiano I: Severe arterial cerebral thrombosis in a patient with protein S deficiency (moderately reduced total and markedly reduced free protein S): A family study. Thromb Haemost 1989;61:144–147.
- Cros D, Comp PC, Beltran G, Gum G: Superior sagittal sinus thrombosis in a patient with protein S deficiency. Stroke 1990;21:633–636.
Prats JM, Garazar C, Zuazo E, Lopez J, Pinan MA, Aragues P: Superior sagittal sinus thrombosis in a child with protein S deficiency. Neurology 1992;42:2303–2305.
- Barinagarrementeria F, Cantu Brito C, Izaguirre R, de la Pena A: Progressive intracrancial occlusive disease associated with deficiency of protein S. Report of two cases. Stroke 1993;24:1752–1756.
Comp PC: Laboratory evaluation of protein S status. Semin Thromb Hemost 1990;16(2):177–181.
- Svensson PJ, Dahlback B: Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994;330:517–522.
- Simioni P, de Ronde H, Prandoni P, Saladini M, Bertina RM, Girolami A: Ischemic stroke in young patients with activated protein C resistance. A report of three cases belonging to three different kindreds. Stroke 1995;26:885–890.
Van der Bom JG, Bots ML, Haverkate F, Slagboom PE, Meijer P, de Jong PT, Hofman A, Grobbee DE, Kluft C: Reduced response to activated protein C is associated with increased risk for cerebrovascular disease. Ann Intem Med 1996;125:265–269.
- Forsyth PD, Dolan G: Activated protein C resistance in cases of cerebral infarction. Lancet 1995;345:795.
- Press RD, Liu XY, Beamer N, Coull BM: Ischemic stroke in the elderly. Role of the common factor V mutation causing resistance to activated protein C. Stroke 1996;27:44–48.
- Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP: Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995;332:912–917.
- Zoller B, He X, Dahlback B: Homozygous APC-resistance combined with inherited type I protein S deficiency in a young boy with severe thrombotic disease. Thromb Haemost 1995;73:743–745.
- van Boven HH, Reitsma PH, Rosendaal FR, Bayston TA, Chowdury V, Bauer KA, Scharrer I, Conard J, Lane DA: Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency. Thromb Haemost 1996;75:417–421.
- Gandrille S, Greengard JS, Alhenc-Gelas M, Juhan-Vague I, Abgrall JF, Jude B, Griffin JH, Aiach M: Incidence of activated protein C resistance caused by the ARG 506 GLN mutation in factor V in 113 unrelated symptomatic protein C-deficient patients. Blood 1995;86:219–224.
Chaturvedi S, Dzieczkowski J: Multiple hematologic abnormalities in young patients with activated protein C resistance and arterial stroke (abstract). Cerebrovasc Dis 1997;7 (suppl 4):58.
- Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR: Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994;344:1453–1457.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.